司库奇尤单抗治疗中重度斑块状银屑病的真实世界用药情况:PROSPECT研究
PROSPECT是一项正在进行的24周单队列非干预研究,中期分析纳入805例接受司库奇尤单抗治疗的中重度银屑病患者。结果显示多数患者疾病负担高,基线平均PASI为17.5,93.4%有高疾病严重度体征;既往系统治疗因不良事件停药在传统系统治疗中较高,转换期时长取决于既往治疗类型。
要点
- 真实世界中司库奇尤单抗患者基线疾病负担高,平均PASI 17.5。
- 传统系统治疗因不良事件停药比例高于生物制剂。
- 转换期时长因既往治疗类型而异,生物制剂最长。
核心结论
- PROSPECT是首个在真实世界环境中调查司库奇尤单抗治疗患者既往和合并银屑病治疗使用情况的研究。
研究设计与样本
- PROSPECT为正在进行的24周、单队列、非干预性研究,本次中期分析报告前805例受试者的基线特征和转换期时长。
主要发现
- 多数受试者为男性(491/796,61.7%),平均年龄47.7岁(SD 13.7)。
- 基线PASI可获取于92.4%(744/805)的受试者,平均基线PASI为17.5(SD 13.1);93.4%(752/805)的受试者有高疾病严重度体征。
- 合并治疗的使用随疾病严重度体征数量增加而增加。
- 纳入前12个月内,分别有10%、40%、28%的受试者最后既往治疗为外用、传统系统或生物制剂治疗,22%未接受任何银屑病治疗。
- 传统系统治疗者因不良事件停药的比例为22.5%(93/413),生物制剂治疗者为2.4%(5/210)。
关键数值与推荐
- 既往外用、传统系统、生物制剂治疗的转换期中位时长分别为14.0天、30.5天、38.0天。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has demonstrated efficacy and safety in patients with moderate to severe psoriasis. However, as per study protocols, transition periods from prior psoriasis treatments of a defined minimal length were required and use of concomitant psoriasis medication was prohibited. There is therefore a lack of data on the effect of shorter transition periods and concomitant psoriasis treatment with other pharmacologically active substances on the effectiveness and safety of secukinumab in routine clinical practice. OBJECTIVES: The PROSPECT study was designed to assess prior and concomitant use of psoriasis treatments in subjects receiving secukinumab and the duration of transition periods from prior treatments to secukinumab. Here, we report the baseline characteristics and the duration of transition period in an interim analysis of the first 805 subjects. METHODS: PROSPECT is an ongoing 24-week, single-cohort, non-interventional study. Subjects with moderate to severe psoriasis with a decision to receive secukinumab were included. RESULTS: The majority of subjects were male (491/796, 61.7%), with a mean age of 47.7 years (SD 13.7). The baseline Psoriasis Area and Severity Index (PASI) was available for 92.4% (744/805) of subjects, and mean baseline PASI was 17.5 (SD 13.1); 93.4% (752/805) of subjects had signs of high disease severity. Use of concomitant treatment increased with the number of signs. Within the last 12 months prior to inclusion, 10%, 40%, and 28% of subjects had received topical, conventional systemic, or biologic treatments as their last prior psoriasis therapy, respectively, and 22% of subjects had not received any psoriasis therapy. Discontinuation of prior treatment due to adverse events was high in subjects with conventional systemic treatment (93/413, 22.5%) compared to biologic treatment (5/210, 2.4%). The median duration of the transition period was 14.0, 30.5, and 38.0 days for prior topical, conventional systemic, and biologic treatments, respectively. CONCLUSION: PROSPECT is the first study to investigate prior and concomitant use of psoriasis treatments in subjects receiving secukinumab in a real-world setting. The majority of the subjects had a high disease burden and use of concomitant treatment increased with disease severity. The duration of the transition period depended on prior treatment.
引用
- Körber A, Thaçi D, von Kiedrowski R, et al. Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study. J Eur Acad Dermatol Venereol. 2017. PMID: 28960469. doi:10.1111/jdv.14604
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。